5-Nitrosothiols may serve as carriers in the mechanism of action of endothelium-derived relaxing factor (EDRF) by stabilizing the labile nitric oxide (NO) radical from inactivation by reactive species in the physiological milieu and by delivering NO to the heme activator site of guanylyl cyclase. Low-molecularweight thiols, such as cysteine and glutathione, form 5-nitrosothiol adducts with vasodilatory and antiplatelet properties, and protein thiols can interact in the presence of NO and/or EDRF to form uniquely stable 5-nitroso-proteins. We now show that the 5-nitroso-proteins, 5-nitroso-albumin, 5-nitroso-tissue type plasminogen activator, and 5-nitroso-cathepsin B, have potent antiplatelet effects with an ICso of approximately 1.5 fiM. In the dog, 5-nitroso-albumin inhibits ex vivo platelet aggregation and significantly prolongs the template bleeding time from 2.15±0.13 (mean±SEM) to 9.70±1.24 minutes. The antiplatelet action of 5-nitroso-proteins is associated with the stimulation of guanylyl cyclase and a significant decrease in flbrinogen binding to platelets. 5-Nitroso-proteins undergo thiol-nitrosothiol exchange with low-molecular-weight thiols to form low-molecular-weight 5-nitroso-thiols, and they also interact directly with the platelet surface, both of which processes facilitate generation of NO. These data suggest that 5-nitroso-proteins are potent antiplatelet agents and may be intermediates in the antiplatelet mechanism of EDRF action. {Arteriosclerosis and Thrombosis 1993;13:791-799)
T he vascular endothelium plays an important role in modulating platelet function. Aggregating platelets secrete serotonin and adenosine diphosphate that bind to receptors on endothelial cells and in turn stimulate the release of endothelium-derived relaxing factor (EDRF). 1 Recent studies suggest that EDRF can prevent platelet adhesion to the endothelium 2 -3 and inhibit platelet aggregation. 4 -7 Chemical and spectrophotometric analyses have led investigators to conclude that at least one form of EDRF is the highly labile nitric oxide (NO) radical. 89 A recent study, however, has also suggested that NO may be released from the endothelium in the form of an 5-nitrosothiol adduct. 10 Formation of an 5-nitrosothiol may stabilize the labile NO radical and preserve its biological activity in an oxidative cellular milieu. Sulfhydryl groups in proteins represent an abundant source of reduced thiol for interaction with NO (or, by way of its derivative cation, the nitrosonium ion, NO + ), and 5-nitroso-proteins form readily under physiological conditions. 11 It has recently been demonstrated that bioactive NO equivalents in plasma are bound predominantly to thiol groups of proteins and that this reservoir may play a role in modulating vasomotor tone. 12 In light of the established antiplatelet properties of NO, we now examine the effects of 5-nitroso-proteins on platelet function. In this study, we 1) show that 5-nitroso-proteins inhibit platelet function, 2) investigate in detail the mechanism of platelet inhibition by these biological NO adducts, 3) demonstrate novel aspects of their biochemical metabolism, and 4) document these inhibitory mechanisms in vitro and in vivo.
cal Co., Milwaukee, Wis. Human fibrinogen (plasminogen free and von Willebrand factor free) was purchased from Enzyme Research Laboratories, South Bend, Ind. Sephadex G-25 was purchased from Pharmacia Fine Chemicals, Uppsala, Sweden. Thrombin was purchased from ICN Immunobiologicals, Costa Mesa, Calif. Iodobeads were purchased from Pierce Chemical Company, Rockford, 111. Soluble calf skin collagen was purchased from Worthington Biochemical Corp., Freehold, N.J. Microcarrier beads (Biosilon) for endothelial cell culture were obtained from Vanguard International, Neptune, N.J. Dulbecco's modified Eagle's medium was purchased from GIBCO Technologies, Grand Island, N.Y. Bleeding time templates were purchased from Organon Teknika Corp., Durham, N.C. Radioimmunoassay kits for cyclic guanosine monophosphate (GMP) were purchased from New England Nuclear, Boston. Phosphate-buffered saline (PBS), pH 7.4, consisted of 10 mM sodium phosphate and 150 mM NaCl. TrisbuflFered saline, pH 7.4, consisted of 10 mM tris(hydroxymethyl)aminomethane and 150 mM NaCl. HEPES-buffered saline (HBS), pH 7.35, consisted of 140 mM NaCl, 6 mM HC1, 6 mM N-(2-hydroxyethyl)piperazine-A r '-(2-ethanesulfonic acid), 2 mM Na 2 HPO 4 , 2 mM MgSO 4 , 0.1% dextrose, and 0.4% BSA.
Synthesis of S-Nitroso-proteins
We examined several thiol-containing proteins of diverse function: (bovine) serum albumin, the most abundant plasma protein and the major source of thiol reducing equivalents (Cys 34) in plasma 13 ' 14 ; t-PA, an endothelium-derived serine protease possessing a single, free cysteine residue (Cys 83) in its epidermal growth factor domain 15 ; cathepsin B, a lysozomal cysteine protease; and plasma, estimated to contain 500 .M free protein-thiol, the predominant source of which is albumin (Cys 34).
14 ' 15 Two methods were used to 5-nitrosate these proteins: 1) proteins were exposed to NO generated from equimolar NaNO 2 in 0.5N HC1 (acidified NaNO 2 ) and 2) proteins were exposed to bovine aortic endothelial cells stimulated to secrete EDRF by exposure to shear force, using established methods.
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The formation of 5-nitroso-proteins was confirmed chemically and spectrophotometrically. 11 5-Nitrosothiol content was quantified by the method of Saville, 18 in which the NO that is displaced from 5-nitrosothiol groups by Hg 2+ is assayed by diazotization of sulfanilamide and subsequent coupling with the chromophore Af-(l-naphthyl)ethylenediamine. The stoichiometries of 5-nitrosothiol bonds per protein molecule for BSA, t-PA, cathepsin B, and plasma were (mean±SEM) 0.85±0.04, 0.88+0.06, 0.90±0.02, and 0.87±0.02, respectively. For plasma, the concentration of free thiol was quantified by using Ellman's reagent 19 and the concentration of 5-nitrosothiol by the method of Saville.
18 Thus, the ratio for plasma represents S-nitrosothiol concentration divided by thiol concentration. Nuclear magnetic resonance spectroscopy of 5-[ 
Carboxyamidation
Blockade of protein thiols by carboxyamidation with iodoacetamide prevented 5-nitrosothiol formation as determined chemically. BSA or t-PA was carboxyamidated by exposure to a 10-fold excess of iodoacetamide for 1 hour at room temperature in the dark and then extensively dialyzed to remove excess iodoacetamide.
Thiol Quantification
Quantification of thiol was performed either in plasma directly or in PBS (pH 7.4) using Ellman's reagent (DTNB). 20 
Endothelial Cell Culture
Bovine aortic endothelial cells were cultured on plastic beads (Biosilon) as previously described. 21 Endothelial cells on beads (ECBs) were exposed to 30 /xM acetylsalicylic acid for 30 minutes, washed three times, and resuspended in PBS. The ECBs were placed in the thiol-containing solutions and stimulated to secrete EDRF by exposure to shear force as previously described. 111617 In these experiments, ECBs were used at a density of 5 x 10 3 cells/^L and exposed to a shear stress of 0.43 dyne/cm 2 for 15 minutes, as calibrated in our laboratory. 17 
Platelets
Venous blood was obtained from volunteers who had not consumed aspirin or other nonsteroidal anti-inflammatory drugs for at least 10 days and was anticoagulated with 13 mM trisodium citrate. Platelet-rich plasma (PRP) was prepared by centrifugation at 150g for 10 minutes at 25°C, and platelet-poor plasma (PPP) was prepared by centrifugation at 800g for 10 minutes. Gel-filtered platelets (GFPs) were obtained by passing PRP over a Sepharose-2B column in calcium-free Tyrode's-HEPES buffer, as previously described. 22 Platelet counts were measured using a Coulter Counter (model ZM, Coulter Electronics, Hialeah, Fla.) and adjusted to 150,000//xL by the addition of PPP or HBS.
Platelet Aggregation and Disaggregation
In platelet aggregation experiments, 200 fiL of PRP or GFPs was incubated with 100 JAL of 5-nitroso-protein for 10 minutes at 37°C in a PAP-4 aggregometer (Biodata, Hatboro, Pa.), after which time aggregation was induced with 5 FIM ADP, 100 Mg/mL collagen, or 0.024 unit/mL thrombin. Aggregation experiments with GFPs were performed in the presence of 0.1 mg/mL fibrinogen; when thrombin was used as an agonist, 2.5 mM L-glycyl-L-prolyl-L-arginyl-L-proline was also added to inhibit (delay) fibrin polymerization. 23 Aggregation was quantified by measuring the rate or extent of change of light transmittance and was expressed as a normalized value relative to control aggregation. Whole-blood aggregation was performed using impedance aggTegometry in a Chronolog Whole Blood Aggregometer (Havertown, Pa.). In aggregations performed with methylene blue, platelets were preincubated for 15 minutes with 10~8 M methylene blue before the addition of agonists or inhibitors of aggregation.
To measure the effects of 5-nitroso-proteins on the dispersal of platelet aggregates, 5-nitroso-proteins were added to PRP or GFPs after maximal aggregation was induced with 5 £tM ADP (corresponding to approximately 60% light transmittance compared with PRP). Disaggregation was quantified by measuring the maximal rate and extent of decrease in light transmittance after the addition of 5-nitroso-proteins.
To exclude irreversible damage to platelets exposed to 5-nitrosated proteins, we examined platelet function after the removal of 5-nitrosated protein by gel filtration. PRP was incubated in the presence of 14 /iM S-nitroso-BSA for 10 minutes or 60 minutes. PRP exposed to BSA or S-nitroso-BSA was then gel filtered on a Sepharose-2B column, and the platelets were counted and adjusted to 150,000//xL by the addition of HBS. Aggregation was then induced with 5 fiM ADP as above and found not to be significantly different (maximal rate of aggregation, 0.85±0.05% transmittance/sec versus 0.88 ±0.03% transmittance/sec, n=6, p=NS, for t=10 minutes; 0.80±0.02% transmittance/sec versus 0.79±0.03% transmittance/sec, n=3, p=NS, for t=60 minutes).
Fibrinogen Binding
Human fibrinogen (free of plasminogen and von Willebrand factor) was radioiodinated with Iodo-beads as previously described. 23 115 I-fibrinogen binding to GFPs stimulated with 5 ^.M ADP was performed as previously described. 24 Specific binding in the presence or absence of 14 /xM 5-nitroso-BSA was determined over a range of fibrinogen concentrations from 0.25 to 2.0 JAM. Nonspecific binding was determined by using a 15-fold excess of unlabeled fibrinogen and accounted for 15% of total binding.
Cyclic Nucleotide Assays
Intraplatelet cyclic GMP was measured by radioimmunoassay. ADP (5 /MM) was added to 300 /xL GFPs incubated in the presence of 14 fiM BSA or 5-nitroso-BSA. After 1 minute, 300 pL of 10% trichloroacetic acid was added. Trichloroacetic acid was removed by ether extraction, and samples were acetylated with acetic anhydride to increase the sensitivity of the assay.
Bleeding Time Determination and Ex Vivo Aggregation
Mongrel dogs of either sex weighing between 20 and 26 kg were anesthetized with 20 mg/kg body wt sodium thiamylal (Boehringer Ingleheim, St. Joseph, Mo.), intubated with a cuffed endotracheal tube, and ventilated with a respirator (Drager AV, North American Drager, Telford, Pa.) with 50% O 2 (22 breaths/min, 10-12 mL/kg body wt per stroke volume). Anesthesia was maintained throughout the experimental protocol with 1-2% halothane. Animals used in this study were maintained in accordance with the guidelines of the Committee on Animals of the institution, and those prepared by the Committee on Care and Use of Labo- Venous and arterial access was achieved, and intravenous doses of BSA or 5-nitroso-BSA were then infused. Ex vivo platelet aggregation (induced by 5 ADP or 0.1 mg/mL collagen) measurements were performed at baseline and 5 minutes after infusion of BSA or 5-nitroso-BSA at 1, 10, or 50 nmol/kg body wt per minute for 5 minutes. Bleeding time measurements were performed at baseline and 5 minutes after bolus infusion of 183 nmol/kg body wt of BSA or 5-nitroso-BSA using a template apparatus applied to the ventral aspect of the tongue to minimize temperature fluctuation.
Protein Determinations
Protein concentrations were determined by the method of Bradford. 23 
Statistical Analysis
Determination of statistical significance was carried out by nonpaired t test or two-way analysis of variance followed by a Newman-Keuls comparison. Values of /?<0.05 were considered significant.
Results

Inhibition of Platelet Function by S-Nitroso-proteins
The effects of 5-nitroso-proteins were first examined using GFPs. 5-Nitroso-BSA inhibited ADP-induced platelet aggregation in a dose-dependent manner (Figure 1) with an apparent IQo of 1.5 /iM. Similar IQoS were measured for aggregation induced by collagen (1.2 fiM) and thrombin (1.3 ^.M). In control experiments, BSA alone had no significant effect on platelet aggregation over the range of concentrations tested. 5-Nitroso-t-PA, 5-nitroso-cathepsin B, and 5-nitrosated plasma also inhibited platelet aggregation ( Table 1) . As shown in Table 1 , 5-nitroso-BSA, 5-nitroso-t-PA, and 5-nitroso-cathepsin B were essentially equipotent, with IQoS of approximately 1.5 ^M. Quantification of 5-nitrosothiol before and after trichloroacetic acid precipitation showed that approximately 95% 5-nitrosothiol was protein bound.
5-Nitroso-proteins were also synthesized by exposure of the proteins to authentic EDRF (NO) from bovine aortic endothelial cells stimulated to secrete EDRF as described in "Methods." 5-Nitroso-proteins synthesized with EDRF also inhibited platelet aggregation ( Figure  1 ). Neither BSA exposed to unstimulated endothelial cells nor PBS incubated with stimulated cells in the absence of BSA inhibited ADP-induced platelet aggregation in PRP. Pretreatment of endothelial cells with acetylsalicylic acid was performed in all cases to eliminate prostanoid synthesis.
The platelet-inhibitory action of 5-nitroso-proteins was also comparable in GFPs and whole-blood preparations. For example, the relative extent of aggregation compared with control for 1.4 /iM 5-nitroso-BSA was 0.54±0.04 (mean±SEM) in GFPs, 0.39±0.13 in PRP, and 0.64±0.03 in whole blood. Disaggregation of platelets by 5-nitroso-proteins was also observed at equivalent concentrations as those inducing inhibition of platelet aggregation (data not shown).
Time Dependence of Antiplatelet Effects of S-Nitroso-proteins
The platelet-inhibitory effect of 5-nitroso-proteins was time dependent. Increasing incubation times led to Adenosine diphosphate-induced platelet aggregation was performed in the presence of bovine serum albumin (BSA), tissue type plasminogen activator (t-PA), cathepsin B, plasma, 5-nitroso (NO)-BSA, S-NO-t-PA, 5-NO-cathepsin B, and a nitrosated protein plasma fraction. The concentration of all proteins and 5-nitroso-proteins was 1.4 fiM. Plasma S-nitroso-protein concentration was quantified by the Saville reaction. 18 Aggregations were not inhibited by the control or nonnitrosated proteins: BSA, 1.0+0.02; t-PA, 0.98±0.07; cathepsin B, 0.96±0.07; and plasma, 0.93±0.04. Values are presented as mean±SEM for n=4-12 experiments.
Protein versus S-nitroso-protein, p<0.007; nitrosated plasma versus S-nitroso-protein, p£0.04.
Transfer of NO From S-Nitroso-proteins to Low-Molecular-Weight Thiols
The stability of 5-nitroso-proteins under physiological conditions, as well as their differential reactivity in PBS and plasma, begs the question of the mechanism by which these stable adducts release and deliver NO to the platelet in the aggregation experiments described here. To address this issue, we examined the effect of low-molecular-weight thiols on protein-bound S-nitrosothiol in a solution of S-nitroso-BSA. We incubated 50 /xM S-nitroso-BSA with an equimolar concentration of reduced glutathione and measured the transfer of NO from BSA to glutathione over time by the Saville reaction 18 after protein precipitation. As shown in Figure 3 , approximately one half of the S-nitroso-BSA was converted to S-nitroso-glutathione after 10 minutes at 25°C. Comparable results were obtained with a cellpermeable, low-molecular-weight thiol, iV-acetylcysteine. The functional correlate of this transfer was examined by showing that increasing concentrations of glutathione led to progressive inhibition of platelet aggregation in the presence of a subthreshold (under these conditions) concentration of S-nitroso-BSA (Figure 4) . The implications of S-nitroso-glutathione-mediated platelet inhibition in these studies is further supported by the comparable potency of this compound synthesized de novo with acidified NaNO 2 (IC 50 =20 MM).
The ability of low-molecular-weight thiols to enhance the inhibitory action of S-nitroso-proteins can account for the action of S-nitroso-BSA in PRP or whole blood; however, in a GFP system, some other mechanism of facilitated transfer of NO must be operative. The platelet surface is another source of reduced thiol equiva- 
FIGURE 2. Effect of increasing incubation time on the degree of platelet inhibition by 140 nM S-nitroso-bovine serum albumin (BSA). Gel-filtered platelets were incubated with 140 nM S-nitroso-BSA for up to 1 hour, and platelet aggregation induced by 5 liM adenosine diphosphate in the presence of 0.1 mg/mL fibrinogen was determined at 1, 10, 30, 45, and 60 minutes during the incubation period as described in "Methods."
lents, and therefore, we tested the ability of GFPs in protein-free buffer (calcium-free Tyrode's-HEPES) to facilitate the removal of NO from 5-nitroso-BSA. GFPs were incubated with 132 fiM 5-nitroso-BSA, and the rate of loss of NO from BSA was determined by centrifuging the platelets from the incubation suspension over time, after which the 5-nitroso-BSA content of the supernatant was measured by the Saville reaction. 18 GFPs facilitated the release of NO from 5-nitroso-BSA 
FIGURE 3. Line plot showing the transfer of nitric oxide (NO) from S-nitroso-proteins to low-molecular-weight thioL S-Nitroso-bovine serum albumin (BSA) (50 \x.M) was incubated with an equimolar concentration of reduced glutathione (GSH) at 25°C, and the distribution of NO between BSA (open circles) and GSH (closed circles) was determined over time by protein precipitation and the Saville reaction 18 (n=2).
at a rate of 5.3±2.7 nmol/min per 10 4 platelets («=4); spontaneous release of NO from 5-nitroso-BSA under these conditions was essentially undetectable (i.e., <0.1 nmol/min per 10 4 platelets). These data support the hypothesis that the platelet surface can also catalyze the release of NO from S-nitroso-proteins and thereby, possibly account for the antiplatelet action of these otherwise stable physiological adducts.
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FIGURE 4. Semilogplot showing effect of increasing concentrations of reduced glutathione (GSH) on the extent of gel-filtered platelet (GFP) aggregation. S-Nitroso-bovine serum albumin (BSA) (15 u.M) was incubated with increasing concentrations of GSH for 5 minutes and subsequently added to GFPs, in which the final concentration of S-nitroso-BSA was 5 IMM. After 2 minutes the extent of aggregation induced by adenosine diphosphate was determined (open circles) in calcium-free Tyrode's-HEPES buffer containing 0.1 mg/mL fibrinogen and compared with that of S-nitroso-BSA (open circle on y axis) and GSH alone (open triangle).
FIGURE 5. Bar graph showing modification of protein thiols by carboxyamidation and effect of methylene blue on the platelet-inhibitory action of S-nitroso-bovine serum albumin (BSA). The relative extent of platelet aggregation induced by 5 u,M adenosine diphosphate in gel-filtered platelets as described in "Methods" was determined for A) BSA (1.4 uM), B) S-nitroso-BSA (1.4 uM), C) iodoacetamide-treated BSA (1.4 u-M) subsequently incubated with acidified NaNO 2 as a source of NO, andD) S-nitroso-BSA (1.4 fiM) after platelets
Inhibition of S-Nitroso-protein Antiplatelet Action
Blockade of protein thiols by carboxyamidation prevented S-nitrosothiol formation, as determined chemically by the method of Saville 18 as well as spectroscopicalry. This modification rendered the proteins exposed to NO or EDRF incapable of inhibiting platelet aggregation ( Figure 5 ).
Effect of S-Nitroso-proteins on Platelet Cyclic GMP and Fibrinogen Binding
Consistent with the mechanism of platelet inhibition by organic nitrates, low-molecular-weight S-nitrosothiols, and EDRF, the platelet-inhibitory effect of S-nitroso-proteins was abolished by methylene blue, an inhibitor of guanylyl cyclase ( Figure 5 ). The importance of cyclic GMP in the mechanism of platelet inhibition by S-nitroso-proteins was confirmed by showing that S-nitroso-BSA (14 /JLM) induced an approximate twofold increase in intraplatelet cyclic GMP compared with basal levels at 1 minute after exposure (n=4; mean±SEM of 0.61 ±0.07 picomoles of cyclic GMP per 10 s platelets compared with a basal level of 0.35±0.04; p=0.022). BSA alone had no effect on cyclic GMP levels.
To elucidate further the mechanism of platelet inhibition by 5-nitroso-proteins, fibrinogen-binding studies were performed in GFPs. Figure 6 shows that exposure of the platelets to S-nitroso-BSA led to a reduction in the number of platelet-bound fibrinogen molecules. S-Nitroso-BSA at a concentration of 14 pM, which inhibited platelet aggregation by 81%, caused a reduc- tion in ADP-stimulated fibrinogen binding of 60% (54,000± 12,000 fibrinogen molecules per platelet in the presence of BSA compared with 22,000±3,000 fibrinogen molecules per platelet in the presence of S-nitroso-BSA; mean±SEM of four experiments; BSA versus S-nitroso-BSA, p=0.04).
Effects of S-Nitroso-proteins on Platelet Function In Vivo
Finally, the biological/physiological relevance of S-nitroso-proteins was investigated in mongrel dogs by following the protocol described in "Methods." A dosedependent inhibition of ex vivo aggregation was apparently induced by ADP (Figure 7 ) or collagen (data not shown) and was accompanied by a significant prolongation of the bleeding time (Table 2) .
Discussion
The experiments presented here demonstrate that NO and EDRF will react with protein thiols to form S-nitroso-protein adducts that are potent platelet-inhibitory compounds in vitro, ex vivo, and in vivo. The mechanism by which exogenous and endogenous nitro(so) derivatives inhibit platelets parallels that for vascular smooth muscle: the free radical NO stimulates guanylyl cyclase by forming a nitrosyl-heme complex at the activator site of the enzyme. 2728 Mellion and coworkers 29 extended these observations to the platelet, confirming that NO inhibits platelets by elevating cyclic GMP. Our laboratory showed that NO-mediated elevation of cyclic GMP results in a marked decrease in the number of fibrinogen molecules bound to the platelet, 24 to an inhibition of intracellular calcium flux, 24 and to an inhibition of platelet secretion. 30 The mechanism by which cyclic GMP leads to these inhibitory effects remains to be defined but may involve protein phosphorylation events regulated by cyclic GMP 31 -33 or signal transduction events involving the phosphoinositide pathway. 33 - 34 The characteristics of the plateletinhibitory response for S-nitroso-proteins described in this study -namely, reversal by methylene blue, elevation of intraplatelet cyclic GMP, and corresponding diminution of fibrinogen binding to the platelet -suggest that 5-nitroso-proteins act through a similar inhibitory mechanism as has been described for organic nitrates and related nitro(so) compounds, In view of the fact that NO is rapidly inactivated by molecular oxygen, 37 superoxide anion, 38 and heme 39 as well as nonheme iron, 40 it has been postulated that NO is stabilized by a carrier molecule that preserves its biological activity. Since Ignarro and coworkers 41 Template bleeding times were performed on the ventral aspect of the tongue after bolus infusion of 183 nmol/kg body wt of 5-nitroso-bovine serum albumin (BSA). Bleeding times were performed before and 5 minutes after infusion of S-nitroso-BSA.
Control bleeding time versus bleeding time after infusion, />=0.0006. onstrated that nitro(so) compounds can react with reduced low-molecular-weight thiols such as cysteine and glutathione to form 5-nitrosothiols, evidence has mounted that supports the view that 5-nitrosothiols may serve such a carrier role as intermediates in the mechanism of nitrate and EDRF action. In platelets in particular, Loscalzo 35 has shown that the reduced thiol 7V-acetylcysteine potentiates the antiplatelet effects of organic nitrates and that the incubation of nitroglycerin in PRP results in intraplatelet glutathione depletion coincident with the formation of 5-nitrosothiols.
The role of reduced thiols in the action of EDRF is more controversial. Palmer and colleagues 8 and Ignarro and coworkers 9 - 39 have separately concluded that EDRF is chemically and spectrophotometrically identical to NO. However, it has recently been proposed that the vasodilatory properties of EDRF more closely resemble those of 5-nitroso-cysteine than of NO, 42 and the possibility that EDRF is released abluminally in the form of a nitroso derivative has been recently entertained. 43 Notwithstanding the controversy over the chemical identity of EDRF, these reports, the findings that /V-acetylcysteine potentiates the antiplatelet effects of EDRF and prolongs its half-life, 1617 and the present demonstration of 5-nitrosothiol formation from endogenous NO, taken together, appear to support strongly the possibility of a role for reduced thiol in the metabolism of EDRF.
The biological importance of protein as a source of reduced thiol for reaction with NO remains to be determined. However, the remarkable prevalence of protein thiols (the most prevalent source of sulf hydryl groups in plasma and a rich source in the cell cytosol) and the highly specialized nature of this functional group suggest that the reaction with NO (through its oxidation to the reactive nitrosonium ion NO + or related nitrosonium-generating species, N2O3 44 ) may be regulated in a manner other than simple diffusional limitation. Several lines of evidence indirectly support the notion that the formation of protein 5-nitrosothiols is of biological importance. First, Fung and coworkers 45 have demonstrated that the thiol of albumin catalyzes the denitrification of nitroglycerin in plasma. Second, thionitrites are proposed intermediates in the enzymatic denitrification of nitroglycerin by glutathione-5-transferase and glyceraldehyde-3-phosphate dehydrogenase. 46 Third, hemoglobin has been shown to react by way of a sulf hydryl with a nitroso derivative of arylhydroxylamine metabolism. 47 Fourth, Mordvintsev and coworkers 48 have documented that platelet inhibition by iron dinitrosyl complexes occurs in association with binding of these complexes to thiols on the platelet surface. Our findings that NO (or NO + ) and EDRF (or a derivative thereof) will react with protein thiols to form stable 5-nitroso-proteins suggest that proteins may need to be considered in the metabolism of EDRF. Several platelet proteins in particular, such as myosin 49 and one type of ADP receptor on the platelet, 50 possess free thiols and are, therefore, potential thiol functional groups for reaction with endogenous NO (or NO + ) by which platelet inhibition may theoretically result.
The precise mechanism(s) by which NO, carried on proteins as a relatively stable 5-nitrosothiol protein adduct, traverses the platelet membrane to enter the cell and thereupon activates guanylyl cyclase is as yet unknown. The potential for transfer of NO from an 5-nitroso-protein to a low-molecular-weight thiol that can, in turn, enter the platelet or facilitate NO transfer to and release at the platelet surface is supported by the data presented here and by recent data from our group. 51 The greater nucleophilicity of low-molecularweight thiols toward NO + as a consequence of their much higher pK's compared with those for certain protein thiols, such as Cys 34 of serum albumin, favors the transfer of NO from protein thiol. 52 In the case of GFPs, platelet surface-catalyzed release of NO must also be considered. In recent studies of nitro(so) vasodilator metabolism in smooth muscle, Fung and coworkers 53 have reported preliminarily that 5-nitrosothiol conversion to NO is mediated by the plasma membrane. These findings are now substantiated and expanded to the platelet by the data presented above and the data of Mordvintsev and colleagues. 48 5-Nitroso-protein formation has pharmacological implications as well. The proteins selected in this study were simply chosen as model compounds for a plasma protein (BSA), an endothelium-derived enzyme (t-PA), and a cysteine protease (cathepsin B) that contain well-characterized, single, free thiols. The possibility that 5-nitroso-protein adducts may be therapeutically useful as antiplatelet agents or vasodilators should be considered.
In summary, we have demonstrated that 1) NO and EDRF will react on exposure to sulfhydryl-containing proteins to form stable 5-nitroso-proteins; 2) 5-nitrosoproteins are potent platelet inhibitors in vitro, ex vivo, and in vivo; 3) the mechanism of platelet inhibition by 5-nitroso-proteins, through increases in cyclic GMP, is similar to that of NO and related nitro(so) compounds; 4) NO is capable of being transferred from 5-nitroso-proteins to low-molecular-weight thiols; and 5) the platelet surface is capable of facilitating the release of NO from 5-nitrosoproteins. These data suggest that 5-nitroso-proteins may serve as intermediates in the cellular metabolism of NO and raise the possibility that this posttranslational modification of protein structure may represent a novel type of cellular regulatory mechanism.
